BOCA RATON, Fla., August 28, 2025--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology clinical trial matching, today announced the launch of its new key feature on the Patient Connect app.
Neuro-symbolic, multi-agent AI system achieves 4x faster trial matching with oncologist-confirmed accuracy across 17,000+ matches, published in ESMO Real World Data and Digital Oncology special issue ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
BOCA RATON, FL, UNITED STATES, August 28, 2025 /EINPresswire.com/ -- Massive Bio, a leader in AI-powered oncology clinical trial matching, today announced the launch ...